Vnitr Lek 2020, 66(3):e58-e62 | DOI: 10.36290/vnl.2020.062

Hepatorenal syndrome - update 2020

Karolína Krátká, Pavla Libicherová, Nikola Mejzlíková, Ivan Rychlík
I. interní klinika 3. LF UK a FN Královské Vinohrady, Praha

Hepatorenal syndrome (HRS) is a serious complication in patients with advanced liver cirrhosis and ascites occurring simultaneously. According to current diagnostic criteria it is considered as one of the less common forms of acute kidney injury (AKI), referred to as HRS-AKI. As a result of the revision of the diagnostic criteria, there was a significant shift in the diagnosis of AKI in patients with liver cirrhosis, allowing early initiation of adequate measures and appropriate treatment. The following article describes the issue of AKI in liver cirrhosis in a wider context, the diagnostic criteria and algorithm of HRS-AKI treatment.

Keywords: acute kidney injury, acute on chronic liver failure, albumin, hepatorenal syndrome, liver cirrhosis, terlipressin.

Published: May 26, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krátká K, Libicherová P, Mejzlíková N, Rychlík I. Hepatorenal syndrome - update 2020. Vnitr Lek. 2020;66(3):e58-62. doi: 10.36290/vnl.2020.062.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62: 986-994. Go to original source... Go to PubMed...
    2. Huelin P, Piano S, Solà E et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute‑on‑chronic‑liver failure. Clin Gastroenterol Hepatol 2017; 15: 438-445. Go to original source... Go to PubMed...
    3. Davenport A, Sheikh MF, Lamb E, et al. Acute kidney injury in acute‑on chronic liver failure: where does hepatorenal syndrome fit? Kidney International 2017; 92: 1058-1070. Go to original source... Go to PubMed...
    4. Solé C, Pole E, Solà E, et al. Hepatorenal syndrome in the era of acute kidney injury. Liver International 2018; 25: 1-11. Go to original source... Go to PubMed...
    5. Belcher JM, Garcia‑Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013; 57: 753-762. Go to original source... Go to PubMed...
    6. Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol 2013; 59: 474-481. Go to original source... Go to PubMed...
    7. Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterology Report 2017; 5: 127-137. Go to original source... Go to PubMed...
    8. Krones E, Fickert P, Zitta S, et al. The chronic kidney disease epidemiology colloboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol 2015; 16: 1-10. Go to original source... Go to PubMed...
    9. Barreto R, Elia C, Solà E, et al. Urinary neutrophil gelatinase‑associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol 2014; 61: 35-42. Go to original source... Go to PubMed...
    10. Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2013; 57: 1-37. Go to PubMed...
    11. Sola E, Kerbert AJ, Verspaget HW, et al. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. J Hepatol 2016; 65: 914-920. Go to original source... Go to PubMed...
    12. Kerbert AJ, Verbeke L, Chiang FW, et al. Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis. PloS One 2015; 10: e0138264. Go to original source... Go to PubMed...
    13. Adebayo D, Morabito V, Davenport A, et al. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int 2015; 87: 509-515. Go to original source... Go to PubMed...
    14. Mandorfer M, Bota S, Schwabl P, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146: 1680-1690. Go to original source... Go to PubMed...
    15. Theocharidou E, Krag A, Bendtsen F, et al. Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis. Liver Int 2012; 32: 1327-1332. Go to original source... Go to PubMed...
    16. Weichselbaum L, Gustot T. The Organs in Acute‑on‑Chronic Liver Failure. Semin Liver Dis 2016; 36: 174-180. Go to original source... Go to PubMed...
    17. Shah N, Mohamed PE, Jover‑cobos M et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int 2013; 33: 398-409. Go to original source... Go to PubMed...
    18. Gustot T, Durand F, Lebrec D, et al. Severe sepsis in cirrhosis. Hepatology 2009; 50: 2022-2033. Go to original source... Go to PubMed...
    19. Bernardi M, Caraceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large‑volume paracentesis: a meta‑analysis of randomized trials. Hepatology 2012; 55: 1172-1181. Go to original source... Go to PubMed...
    20. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406-460. Go to original source... Go to PubMed...
    21. Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol 2014; 4: 302-311. Go to original source... Go to PubMed...
    22. Afinogenova Y, Tapper EB. The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent. Gastroenterol Rep (Oxf) 2015; 3: 216-221. Go to original source... Go to PubMed...
    23. Salerno F. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose‑response meta‑analysis. BMC Gastroenterol 2015; 55: 1-11. Go to original source... Go to PubMed...
    24. Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology 2016; 63: 983-992. Go to original source... Go to PubMed...
    25. Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56: 1293-1298. Go to original source... Go to PubMed...
    26. Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology 2015; 62: 567-574. Go to original source... Go to PubMed...
    27. European Association for the Study of the Liver. EASL clinical practise guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.